D609 protects retinal pigmented epithelium as a potential therapy for age-related macular degeneration

Bowen Wang,Li Wang,Sijie Gu,Yankun Yu,Huaxing Huang,Kunlun Mo,He Xu,Fanzhu Zeng,Yichen Xiao,Lulu Peng,Chunqiao Liu,Nan Cao,Yizhi Liu,Jin Yuan,Hong Ouyang

DOI: https://doi.org/10.1038/s41392-020-0122-1

IF: 39.3

2020-01-01

Signal Transduction and Targeted Therapy

Abstract:Accumulated oxidative damage may lead to irreversible retinal pigmented epithelium (RPE) cell death, which is considered to be the primary cause of dry age-related macular degeneration (AMD), leading to blindness in the elderly. However, an effective therapy for this disease is lacking. Here, we described a robust high-content screening procedure with a library of 814 protective compounds and found that D609 strongly protected RPE cells from sodium iodate (SI)-induced oxidative cell death and prolonged their healthy survival. D609 effectively attenuated excessive reactive oxygen species (ROS) and prevented severe mitochondrial loss due to oxidative stress in the RPE cells. Surprisingly, the potent antioxidative effects of D609 were not achieved through its own reducibility but were primarily dependent on its ability to increase the expression of metallothionein. The injection of this small water-soluble molecule also showed an explicit protective effect of the RPE layer in an SI-induced AMD mouse model. These findings suggested that D609 could serve as a novel antioxidative protector of RPE cells both in vitro and in vivo and unveiled a novel antioxidative mechanism of D609, which may ultimately have clinical applications for the treatment of AMD.